The Metabolic Reset

Archival Status

The Metabolic Reset protocol pairs 5-Amino-1MQ (NNMT inhibitor) with MOTS-c (mitochondrial peptide) to address metabolic dysfunction at two complementary levels: intracellular NAD+ and SAM availability (5-Amino-1MQ) and mitochondrial bioenergetic efficiency (MOTS-c). NNMT (nicotinamide N-methyltransferase) is highly expressed in white adipose tissue and is upregulated in obesity and type 2 diabetes. It consumes SAM to methylate nicotinamide, generating methyl-NAM and lowering cellular NAD+ concentrations in adipose tissue. This suppresses SIRT1-mediated metabolic activity, reducing the expression of genes involved in fatty acid oxidation and thermogenesis. 5-Amino-1MQ inhibits this enzyme, restoring NAD+ and SAM levels, activating SIRT1, and shifting the adipose transcriptome toward a more metabolically active phenotype. Animal studies demonstrate that NNMT inhibition reduces fat mass, improves insulin sensitivity, and normalizes dyslipidemia in diet-induced obesity models without the cardiovascular risks associated with some stimulant-based metabolic agents. MOTS-c activates AMPK through a mechanism involving impaired mitochondrial folate metabolism, which increases cellular AMP/ATP ratio and triggers the energy-sensing response. AMPK activation drives mitochondrial biogenesis via PGC-1alpha, increases glucose uptake via GLUT4 translocation, inhibits lipid synthesis, and activates autophagy for mitochondrial quality control. MOTS-c levels decline with age and in insulin-resistant states, supporting the concept of exogenous restoration as a metabolic intervention. The synergy between these two compounds operates at different cellular compartments: 5-Amino-1MQ works primarily in the adipocyte nucleus and cytoplasm (NAD+ and SAM metabolism), while MOTS-c signals from the mitochondria to the nucleus (retrograde signaling) and to systemic metabolism via circulation. Together, they address both the fuel storage side (reduced adipogenesis and improved lipolysis) and the fuel utilization side (improved mitochondrial ATP production efficiency). This protocol is studied for metabolic syndrome, insulin resistance, age-associated metabolic decline, and obesity-related adipose dysfunction. Both compounds are administered subcutaneously.